pulmonx corp - LUNG
LUNG
Close Chg Chg %
2.21 -0.11 -4.98%
Pre-Market
2.10
-0.11 (4.98%)
Volume: 424.19K
Last Updated:
Jan 8, 2026, 4:00 PM EDT
Company Overview: pulmonx corp - LUNG
LUNG Key Data
| Open $2.19 | Day Range 2.07 - 2.23 |
| 52 Week Range 1.31 - 9.37 | Market Cap $96.11M |
| Shares Outstanding 41.25M | Public Float 35.86M |
| Beta 0.11 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.41 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 752.62K |
LUNG Performance
| 1 Week | -8.70% | ||
| 1 Month | -17.00% | ||
| 3 Months | 32.91% | ||
| 1 Year | -68.93% | ||
| 5 Years | -96.61% |
LUNG Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About pulmonx corp - LUNG
Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.
LUNG At a Glance
Pulmonx Corp.
700 Chesapeake Drive
Redwood City, California 94063
| Phone | 1-650-364-0400 | Revenue | 83.79M | |
| Industry | Medical Specialties | Net Income | -56,394,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 22.008% | |
| Fiscal Year-end | 12 / 2025 | Employees | 291 | |
| View SEC Filings |
LUNG Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.169 |
| Price to Book Ratio | 3.148 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.05 |
| Enterprise Value to Sales | 2.629 |
| Total Debt to Enterprise Value | 0.256 |
LUNG Efficiency
| Revenue/Employee | 287,934.708 |
| Income Per Employee | -193,793.814 |
| Receivables Turnover | 5.616 |
| Total Asset Turnover | 0.483 |
LUNG Liquidity
| Current Ratio | 5.575 |
| Quick Ratio | 4.883 |
| Cash Ratio | 4.163 |
LUNG Profitability
| Gross Margin | 73.877 |
| Operating Margin | -66.819 |
| Pretax Margin | -66.708 |
| Net Margin | -67.305 |
| Return on Assets | -32.536 |
| Return on Equity | -55.255 |
| Return on Total Capital | -39.636 |
| Return on Invested Capital | -38.516 |
LUNG Capital Structure
| Total Debt to Total Equity | 65.81 |
| Total Debt to Total Capital | 39.69 |
| Total Debt to Total Assets | 33.672 |
| Long-Term Debt to Equity | 61.202 |
| Long-Term Debt to Total Capital | 36.911 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Pulmonx Corp - LUNG
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 48.42M | 53.66M | 68.67M | 83.79M | |
Sales Growth
| +47.91% | +10.84% | +27.98% | +22.01% | |
Cost of Goods Sold (COGS) incl D&A
| 12.79M | 13.80M | 18.32M | 21.89M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 3.16M | 4.00M | 1.95M | 1.59M | |
Depreciation
| 3.06M | 3.90M | 1.45M | 1.39M | |
Amortization of Intangibles
| 100.00K | 100.00K | 100.00K | 100.00K | |
COGS Growth
| +10.88% | +7.91% | +32.80% | +19.46% | |
Gross Income
| 35.63M | 39.87M | 50.35M | 61.90M | |
Gross Income Growth
| +68.05% | +11.89% | +26.31% | +22.94% | |
Gross Profit Margin
| +73.59% | +74.29% | +73.32% | +73.88% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 82.93M | 98.50M | 112.29M | 117.89M | |
Research & Development
| 13.06M | 15.40M | 18.08M | 15.85M | |
Other SG&A
| 69.87M | 83.11M | 94.21M | 102.03M | |
SGA Growth
| +54.92% | +18.77% | +13.99% | +4.99% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 1.72M | - |
EBIT after Unusual Expense
| (47.30M) | (58.64M) | (61.94M) | (57.70M) | |
Non Operating Income/Expense
| (185.00K) | 1.13M | 4.89M | 5.32M | |
Non-Operating Interest Income
| 400.00K | 1.53M | 5.57M | 5.06M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 829.00K | 1.07M | 3.23M | 3.51M | |
Interest Expense Growth
| -73.94% | +28.59% | +203.19% | +8.51% | |
Gross Interest Expense
| 829.00K | 1.07M | 3.23M | 3.51M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (48.32M) | (58.57M) | (60.27M) | (55.89M) | |
Pretax Income Growth
| -50.91% | -21.22% | -2.91% | +7.26% | |
Pretax Margin
| -99.80% | -109.15% | -87.76% | -66.71% | |
Income Tax
| 343.00K | 353.00K | 571.00K | 500.00K | |
Income Tax - Current - Domestic
| 46.00K | 66.00K | 62.00K | 53.00K | |
Income Tax - Current - Foreign
| 321.00K | 232.00K | 483.00K | 471.00K | |
Income Tax - Deferred - Domestic
| (19.00K) | 46.00K | 17.00K | 15.00K | |
Income Tax - Deferred - Foreign
| (5.00K) | 9.00K | 9.00K | (39.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (48.66M) | (58.92M) | (60.84M) | (56.39M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (48.66M) | (58.92M) | (60.84M) | (56.39M) | |
Net Income Growth
| -50.98% | -21.09% | -3.26% | +7.31% | |
Net Margin Growth
| -100.51% | -109.80% | -88.60% | -67.30% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (48.66M) | (58.92M) | (60.84M) | (56.39M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (48.66M) | (58.92M) | (60.84M) | (56.39M) | |
EPS (Basic)
| -1.3469 | -1.5884 | -1.6022 | -1.4419 | |
EPS (Basic) Growth
| -49.16% | -17.93% | -0.87% | +10.00% | |
Basic Shares Outstanding
| 36.13M | 37.10M | 37.97M | 39.11M | |
EPS (Diluted)
| -1.3469 | -1.5884 | -1.6022 | -1.4419 | |
EPS (Diluted) Growth
| -49.16% | -17.93% | -0.87% | +10.00% | |
Diluted Shares Outstanding
| 36.13M | 37.10M | 37.97M | 39.11M | |
EBITDA
| (44.14M) | (54.64M) | (59.99M) | (54.39M) | |
EBITDA Growth
| -38.24% | -23.77% | -9.79% | +9.32% | |
EBITDA Margin
| -91.18% | -101.82% | -87.35% | -64.92% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 6.40 | |
| Number of Ratings | 6 | Current Quarters Estimate | -0.349 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -1.337 | |
| Last Quarter’s Earnings | -0.40 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.463 | Next Fiscal Year Estimate | -0.912 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 6 | 5 |
| Mean Estimate | -0.35 | -0.33 | -1.34 | -0.91 |
| High Estimates | -0.30 | -0.28 | -1.22 | -0.44 |
| Low Estimate | -0.39 | -0.39 | -1.55 | -1.17 |
| Coefficient of Variance | -10.74 | -11.16 | -8.50 | -30.70 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Pulmonx Corp - LUNG
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Pulmonx Corp - LUNG
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 24, 2025 | Glendon E. French Director | 991,974 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.85 per share | 7,786,995.90 |
| Mar 6, 2025 | David A. Lehman GENERAL COUNSEL | 175,496 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.97 per share | 1,398,703.12 |
| Mar 6, 2025 | Mehul Joshi Chief Financial Officer & PAO | 221,986 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Mehul Joshi Chief Financial Officer & PAO | 113,986 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.12 per share | 811,580.32 |
| Mar 6, 2025 | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | 393,278 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | 285,278 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.12 per share | 2,031,179.36 |
| Mar 6, 2025 | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | 287,295 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.14 per share | 2,051,286.30 |
| Mar 6, 2025 | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | 289,622 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.12 per share | 2,062,108.64 |
| Mar 6, 2025 | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | 290,537 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.12 per share | 2,068,623.44 |
| Mar 6, 2025 | David A. Lehman GENERAL COUNSEL | 283,496 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Steven S. Williamson PRESIDENT AND CEO; Director | 194,342 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.14 per share | 1,387,601.88 |
| Mar 6, 2025 | David A. Lehman GENERAL COUNSEL | 189,118 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.14 per share | 1,350,302.52 |
| Mar 6, 2025 | David A. Lehman GENERAL COUNSEL | 191,515 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.14 per share | 1,367,417.10 |
| Mar 6, 2025 | David A. Lehman GENERAL COUNSEL | 196,005 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.14 per share | 1,399,475.70 |
| Mar 6, 2025 | David A. Lehman GENERAL COUNSEL | 197,182 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.14 per share | 1,407,879.48 |
| Mar 6, 2025 | Steven S. Williamson PRESIDENT AND CEO; Director | 128,395 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Steven S. Williamson PRESIDENT AND CEO; Director | 376,038 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |